Kornimate/medical-research-clean huggingface dataset:
semi-supervised exercise program before bariatric surgery

Conditions: Morbid Obesity; Exercise; Bariatric Surgery

Summary: background: patients awaiting bariatric surgery, apart from suffering higher bmi, show a large number of comorbidities and a low physical fitness. these factors are associated with a longer surgery time, a longer hospital stay and a greater number of operative complications. to reduce these disadvantages, a nutritional intervention is performed to reduce total weight and the comorbidities associated with obesity prior to surgery. however, the prescription of an exercise program, which can be an effective tool to improve these factors, is not usually part of the usual care of these patients. objective: to know the effects of a semi-supervised exercise program on body composition, cardiovascular risk factors and operative complications in bariatric patients. methods: approximately 3 months before surgery, 60 patients awaiting bariatric surgery will be recruited. patients will be randomized into two groups: a) an experimental group (n = 30); b) a control group (n = 30). the experimental group will perform a semi-supervised exercise program, while the control group will only perform the corresponding evaluations. both groups will be assessed for body composition, cardiovascular risk factors, physical condition, quality of life and physical activity levels at the beginning and at the end of the intervention. in addition, surgery time, hospital length of stay and operative complications will be evaluated in both groups.


Eligibility criteria:
inclusion criteria: * age between 20-55 years. * all patients awaiting bariatric surgery. exclusion criteria: * patients with chronic respiratory diseases * patients with cardiovascular diseases * inability to perform exercise
safety and performance of the da vinci sp® surgical system in colorectal procedures

Conditions: Colorectal Neoplasms

Summary: the study is a prospective, single-center, single-arm unblinded clinical investigation. the aim of this study is to evaluate the performance and safety of da vinci sp system. this study will entail a collection of demographics, preoperative, perioperative and postoperative outcomes of the patients into a database to follow this report on the outcomes, and notably answer questions to demonstrate the performance and safety of this surgical option. all patients being considered for minimally invasive colorectal surgery will be evaluated for participation in the above study. all of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery


Eligibility criteria:
inclusion criteria: * age ≥18 years * pathological confirm of colon or rectal cancer * clinical stage i-iii * patient is a candidate for minimally invasive right hemicolectomy or anterior resection. * asa ≤3 * performance status: ecog 0-1 exclusion criteria: * emergency surgery * patient has metastatic disease * patient has a bleeding or clotting disorder * uncontrolled illness, including active infection, symptomatic heart failure, unstable angina or cardiac arrhythmias, or psychiatric illness that would limit compliance with study requirements * previous laparotomy history * patient unable to provide informed consent * patient is pregnant * bmi 35.0 or higher

Keywords: colorectal cancer robotic surgery
new mrt imaging biomarkers and treatment with kinetic oscillatory stimulation (kos) in nasal cavity for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs)

Conditions: Myalgic Encephalomyelitis; Chronic Fatigue Syndrome

Summary: placebo controlled trial study of efficacy of kinetic oscillation stimulation (kos) in nasal cavity will be conducted in patients with myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs). the outcome of the treatment will be assessed with clinical evaluation of patients, cognitive tests, structural and functional mri of the brain.

myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) is a neurologic disease that is characterized by extreme physical and mental fatigue. although some signs of inflammation have been reported previously in me/cfs patients, the data have been quite limited and controversial. a recent study based on multiplex array of a luminex system has demonstrated an immune signature of serum cytokines that is correlated with the disease severity and fatigue duration. results from resting-state functional mri (fmri) studies have also demonstrated that there is a significant correlation between the degree of chronic fatigue and reduction of functional network connectivity in the brain. the autonomic nervous system (ans) plays an important role in the regulation of systemic inflammation. the nasal cavity has a rich innervation of cranial nerves. we have recently developed a non-invasive ans stimulation technique, called kinetic oscillation stimulation (kos) in the nasal cavity. kos treatment is expected to have a positive impact on systemic inflammation via the restoration of ans homeostasis. with this double blinded, placebo controlled, clinical trial, the efficacy of kos treatment on me/cfs will be assessed by clinical evaluation, multiplex immunoassay of peripheral blood samples, performance of psychomotor vigilance task, structural and functional mri of the brains at the baseline point before kos treatment and after the completion of kos treatment period.

Eligibility criteria:
inclusion criteria: * diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) established by consultant in neurology. exclusion criteria: * any cardiovascular disease. * any other condition considered by the physician to render the patient unsuitable for participation in the study.

Keywords: myalgic encephalomyelitis chronic fatigue syndrome kinetic oscillatory stimulation in nasal cavity
magnetic resonance imaging (mri) of tumor response and cognitive impairment in breast cancer patients undergoing chemotherapy

Conditions: Breast Cancer

Summary: we will use magnetic resonance imaging (mri) to investigate tumor changes in women with breast cancer who are receiving anthracycline-based systemic chemotherapy. we will also use mri and cognitive tests to study the possible effects of chemotherapy on the brains of these women. the results will be compared to a control group of normal healthy women. we will try to determine if mri can be used to predict tumor response and cognitive changes related to the chemotherapy.

in this work we will utilize conventional magnetic resonance imaging as well as a set of advanced magnetic resonance imaging tools to investigate changes in tumor physiology and the human brain resulting from anthracycline-based systemic chemotherapy. we will recruit up to 15 subjects diagnosed with breast cancer and preparing for an anthracycline-based systemic chemotherapy regimen. each subject will undergo the set of mr imaging tools before therapy, after one therapy session, after four therapy sessions, and at the conclusion of therapy. conventional mri methods will be used to quantify tumor-response to chemotherapy for each subject. a control group of up to 15 normal subjects will also be recruited and will undergo mr brain imaging twice with a gap of 6 months between scans. all subjects will also undergo a battery of neuropsychological tests at each imaging session. the results of the neuropsychological tests will be used to quantify cognitive changes for each subject. a final analysis will determine if the advanced mr modalities can be used to predict the response of tumors or human cognition to chemotherapy.

Eligibility criteria:
inclusion criteria: * diagnosed with adenocarcinoma(er+ve, pr+ve) * prescribed, but not yet begun, anthracycline based systemic chemotherapy * not prescribed avastin * able to read and write in english * have signed informed consent exclusion criteria: * diagnosed psychiatric disorder * conditions that would preclude mri (pacemaker, metal objects in body, claustrophobia, pregnancy, etc.) * serious, unstable medical or mental illness * medical contraindication to any study procedure * current alcohol or other substance use disorder (excluding nicotine) * have not read and signed informed consent, or do not understand its contents

Keywords: breast cancer magnetic resonance imaging anthracycline based systemic chemotherapy tumor response cognitive impairment chemo brain
salmeterol/fluticasone easyhaler in the treatment of asthma and copd

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: a non-interventional study to assess the clinical effectiveness of salmeterol/fluticasone easyhaler to achieve and maintain asthma or copd control.

a prospective, open-label, non-interventional, multicentre study in adult patients with asthma or copd who are treated with salmeterol/fluticasone easyhaler. during the study the salmeterol/fluticasone easyhaler will be used according to the summary of product characteristics. clinical effectiveness of the treatment will be evaluated with change in asthma or copd symptoms during 12 weeks treatment.

Eligibility criteria:
main inclusion criteria: 1. male or female patients with asthma or copd who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the study 2. age ≥18 years. 3. written informed consent obtained. main exclusion criteria: 1. pregnant or lactating female patients. 2. participation in other clinical studies during the study. 3. known hypersensitivity (allergy) to salmeterol, fluticasone propionate or the excipient lactose 4. any significant medical disease or condition or other factor that might interfere with study assessments or study participation.
bipap vision versus optiflow system comparison in acute respiratory failure after cardio thoracic surgery

Conditions: Respiratory Insufficiency

Summary: the optiflow ™ use is becoming more common in acute respiratory failure cases, but its place in relation to vni (bi-pap mode) is not yet defined. optiflow ™ vs the vni comparison of the use, in the immediate postoperative period, should lead to define the role of each technique and lead to a optimal rationalization of patients management with acute respiratory failure after surgery.

main objective: to determine, if the initiation of optiflow™ system immediate after cardio/ thoracic surgery with acute respiratory failure or immediate after post extubation in patients at risk, is not less than the start a vni per bipap vision ®system. in terms of reintubation rates, refusal to continue the technique, or switch to another technique proposed. secondary objectives: * to assess changes in the sensation of dyspnea * to analyze the skin tolerance and the comfort in this population * to analyze the evolution of hemodynamic and respiratory parameters * to compare the number of bronchoscopy performed during the patient's stay in intensive care unit * assess the number of postoperative pneumonia and antibiotic consumption * to determine whether the initiation of any treatment changes in the immediate postoperative length of stay in intensive care and comprehensive.

Eligibility criteria:
inclusion criteria: * patients after cardiac/thoracic surgery with acute respiratory failure defined by the presence of the following criteria: * report pao2/fio2 \<300 * respiratory rate\> 25 for at least 2 hours * getting involved accessory respiratory muscles * paradoxical breathing or * in immediate after extubation, the patient will be eligible if present in the withdrawal test: * sao2 \<90% in 12 l of o2 during a trial of spontaneous ventilation tube on * pao2 \<10 kpa at a fio2 ≥ 50% during a vs trial + pressure support * the presence of a risk factor: obesity (bmi\> 30), fevg \<40%, failed extubation prior, stridor exclusion criteria: * previous history of sas * patient tracheotomy * comas non hypercapnic * bradypnea * cardiac arrest * gastric surgery recent * restlessness, lack of cooperation * nausea, vomiting * hemodynamic instability

Keywords: respiratory insufficiency cardiothoracic surgery ventilation system
progress of mild alzheimer's disease in participants on acupuncture versus sham acupuncture

Conditions: Alzheimer Disease 1

Summary: to determine if adjunctive acupuncture acts as an ad treatment rather than a placebo, and identify if benefits are linked to shifts of the gut microbiota.

acupuncture is used as an adjuvant therapy for alzheimer's disease (ad), but available evidence for efficacy is weak. growing studies suggest that resident gut microbiota contributes to the development and progression of ad. acupuncture is reported to treat gastrointestinal and neurodegenerative disorders via the gut-brain axis. the aim is to determine if adjunctive acupuncture acts as an ad treatment rather than a placebo, and identify if benefits are linked to shifts of the gut microbiota. this is a randomized, participant-masked, sham-controlled trial. one hundred and sixty participants with mild ad will be randomly assigned (1:1) to either active acupuncture or non-penetrating sham acupuncture (3 times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks). the primary efficacy outcome is the change from baseline to week 28 in the alzheimer's disease assessment scale (adas-cog12). secondary efficacy outcomes include other assessments of the mini-mental state examination (mmse), the alzheimer's disease cooperative study-activities of daily living (adcs-adl), neuropsychiatric inventory (npi) and gut microbiota.

Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria for probable ad according to the national institute of neurological and communicative disorders and stroke/alzheimer's disease and related disorders association (nincds/adrda) * scored 1.0 by the clinical dementia rating scale (cdr) global score exclusion criteria: * dementia due to other causes * evidence of a clinically relevant or unstable psychiatric disorder * has irritable bowel syndrome or inflammatory bowel disease * has unstable or severe cardiovascular, hepatic, renal, respiratory, endocrinologic, neurologic diseases and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study * has visual or hearing disorder, defeating completion of evaluation * use of ad therapy (except for donepezil hydrochloride) which cannot be stopped * use of antibiotics within 1 month prior to enrollment * has a history of gastrointestinal surgery (except for appendicitis and hernia surgery) * without a reliable caregiver who will accompany the participant during treatment and assessment, and monitor administration of the prescribed medications * with cardiac pacemaker or metal allergy * once experienced electroacupuncture treatment before at any time (manual acupuncture is allowed) * premenopausal woman

Keywords: alzheimer's disease electroacupuncture
rhomboid intercostal and subserratum plane block for minimally invasive esophagectomy

Conditions: Esophagus Cancer

Summary: the objective is to investigate the safety and effectiveness of rhomboid intercostal and subserratum plane (riss) block for postoperative analgesia after minimally invasive mckeown esophagectomy (mie-mckeown).

rhomboid intercostal and subserratum plane block (riss) is a nerve block technique in which local anesthetics are injected into the rhomboid-intercostal muscle planes and the serratus anterius-intercostal muscle planes, and the intercostal nerve is blocked by diffusion of local anesthetics. it is confirmed that riss can provide analgesia not only in the front half of the chest, but also in the upper abdomen. however, the efficacy of riss in minimally invasive surgery for esophageal cancer has not been proven. the investigators placed catheters on the riss plane and continuously injected local anesthetics to investigate whether riss is effective and safe in minimally invasive esophageal cancer surgery.

Eligibility criteria:
inclusion criteria: * patients received mie-mckeown surgery and were confirmed by postoperative pathology; age 18-75 years old * body mass index (bmi) : 18.5\~23.9kg/m2; * american society of anesthesiologists (asa) grade: ⅰ\~ⅱ; * clear consciousness, no cognitive impairment; * patients informed to participate in the study and signed informed consent. exclusion criteria: * infection of the puncture site, abnormal platelet or coagulation function; * patients with drug allergy involved in this study; * long-term use of analgesic, sedative drugs or a history of heavy drinking; * patients with chronic painful diseases; * with severe heart, liver, kidney and lung dysfunction; * infectious diseases, blood, immune, circulatory system diseases; -communication barriers, can not cooperate with the scale assessment; - * other situations not suitable for this study.

Keywords: rhomboid intercostal and subserratum plane block ultrasound-guided postoperative analgesia minimally invasive esophagectomy
assessing and reducing risk of violent re-injury among victims of urban violence

Conditions: Violence

Summary: the purpose of the study is to develop a program to help people to lower their chances of being violently injured again.


Eligibility criteria:
inclusion criteria: * age between 18-65 years * intentionally injured in community violence. * admitted to a level 1 trauma center * able to provide voluntary informed consent exclusion criteria: * under the age of 18 or over the age of 55. * not fluent in the english language * patients with suspected mental retardation or active psychosis as determined by brief clinical screen. * patients currently in legal detention status
australia and new zealand adult extracorporeal membrane oxygenation (ecmo) audit 2005

Conditions: Respiratory Distress Syndrome, Adult; Respiratory Insufficiency; Shock, Cardiogenic

Summary: extracorporeal membrane oxygenation (ecmo) is a means of artificially performing the function of the human lung and/or heart outside the body. its use is escalating in a wide range of clinical settings in the adult population without evidence or guidelines to support this practice. this study involves a nationwide questionnaire which has two components. the initial pilot survey will attempt to identify all institutions currently practicing ecmo or those intending to do so in the future, and are willing to participate in prospective data collection. the second phase will involve a monthly survey of these centres regarding the extent of ecmo use, practice details implemented, and outcome data. it is hoped that the collection of this information will later assist in the development of guidelines for this expensive and presently unsubstantiated practice, together with the construction of appropriate training programs for staff.


Eligibility criteria:
inclusion criteria: * patients receiving ecmo in australia and new zealand

Keywords: lung transplantation heart transplantation
the combination of prednisone and recombinant human thrombopoietin for treatment of immune thrombocytopenia in pregnancy

Conditions: Immune Thrombocytopenia

Summary: randomized, open-label study to compare the efficacy and safety of prednisone plus recombinant human thrombopoietin (rhtpo) compared to prednisone monotherapy for the treatment of immune thrombocytopenia in pregnancy

the investigators are undertaking a parallel group, randomized controlled trial of adults with itp in pregnancy in china. patients were randomized to prednisone plus rhtpo and prednisone monotherapy group. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: 1. age 18-49; 2. gestational weeks ≥20 weeks; 3. platelet count \<30×10\^9/l, accompanied with or without bleeding symptoms; 4. confirmed diagnosed, treatment-naive itp in pregnancy; 5. willing and able to sign written informed consent. exclusion criteria: 1. secondary itp such as drug-related thrombocytopenia; 2. thrombocytopenia caused by viral infection (hiv, hepatitis b or hepatitis c); other autoimmune diseases (including positive anti-nuclear antibodies, positive anti-cardiolipin antibodies, positive lupus anticoagulant factors, and positive coombs) with severe heart, kidney, liver or respiratory dysfunction; 3. severe immunodeficiency; 4. myelodysplastic or myeloid fibrosis; 5. history of malignancy.
artificial shrinkage of fresh blastocysts

Conditions: Infertility Assisted Reproductive Technology

Summary: the aim of the study is to determine if collapsing an embryo (or making it fold compactly by taking away its fluid) before the transfer in the uterine cavity improves pregnancy rates in assisted reproductive technology (art). women coming to our art center will be randomized in two groups : the collapsing group and a control group. pregnancy rates will be compared in the two groups. a biomarker (cell free dna) will also be determined in each group and correlated to pregnancy occurrence.

this is a prospective randomized study designed to determine if artificial shrinkage (as) before transfer of embryos impact clinical pregnancy rate in single blastocyst embryo transfer (sbet) cycle. women elected for sbet will be randomized on transfer day in two arms:the as group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer and a control group. clinical pregnancy rates will be compared. secondarily, rate of monozygotic twin pregnancy and cell free dna concentration in culture medium will be evaluated in the two groups.

Eligibility criteria:
inclusion criteria: * couple eligible for a transfer of a single embryo at the blastocyst stage * available couple for a follow up of 12 months exclusion criteria: * attempt with frozen embryo or frozen oocyte * attempt with a pre-implantation diagnosis * patient has not signed informed consent * couple in a period of exclusion determined by a previous study * couple under legal protection, guardianship or guardianship

Keywords: single blastocyst embryo transfer artificial shrinkage clinical pregnancy rate cell free
the efficacy of estratest® tablets in relieving menopausal symptoms in estrogenized, non-hysterectomized postmenopausal women

Conditions: Menopause

Summary: to determine whether treatment with estratest® tablets is superior to treatment with esterified estrogens tablets


Eligibility criteria:
inclusion criteria: non-hysterectomized, menopausal women between the ages of 35 and 65 years (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the investigator's clinical judgement

Keywords: menopause; postmenopause; estrogen; hormone therapy
refractory chronic cluster headache: exploring the potential of repetitive transcranial magnetic stimulation

Conditions: Refractory Chronic Cluster Headache

Summary: the goal of this clinical trial is to learn if drug abc works to treat severe asthma in adults. it will also learn about the safety of drug abc. the main questions it aims to answer are: does transcranial magnetic stimulation lower the number of attacks per week in patients with refractory cluster headache ? researchers will compare transcranial magnetic stimlation to a sham stimulation (a look-alike stimulation) to see if it works to prevent attacks of cluster headache. participants will: recieve stimulation for 10 minutes for 10 consecutive working days in 2 periods of time, separated by a 1 month washout period. visit the clinic for each treatment day. keep a diary of their symptoms and the number of times they use a rescue medication


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosed with chronic cluster headache (cch) based on the international classification of headache disorders 3rd edition * diagnosed with refractory cch based on the european headache federation criteria of 2014. exclusion criteria: * history of epilepsy. * concomitant diagnosis of any other headache (if the patient was unable to differentiate between them). * carriers of any electronic device, or any additional contraindication for transcranial magnetic stimulation, such as pregnancy.